BAUDAX BIO INC (BXRX) 1.55 -0.01 (-0.64%)
1.55 -0.01 (-0.64%)
US07160F4046 - Common Stock
Fundamental Rating
Taking everything into account, BXRX scores 2 out of 10 in our fundamental rating. BXRX was compared to 255 industry peers in the Pharmaceuticals industry. BXRX has a bad profitability rating. Also its financial health evaluation is rather negative. BXRX is valued quite expensive, but it does show an excellent growth.
Note: BXRX has only limited data available, so a full analysis was not possible, which makes the total rating unfair.
Profitability
Profitability Rating
BXRX has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for BXRX.
VS Industry
Valuation
Valuation Rating
BXRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BXRX. No positive earnings are expected for the next year.
VS Industry
Growth
Growth Rating
The Earnings Per Share has grown by an impressive 64.14% over the past year.
The Earnings Per Share is expected to grow by 25.85% on average over the next 5 years. This is a very strong growth
Looking at the last year, BXRX shows a quite strong growth in Revenue. The Revenue has grown by 17.38% in the last year.
BXRX is expected to show a strong growth in Revenue. In the coming 5 years, the Revenue will grow by 84.20% yearly.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | 64.14% | 97.79% | 40.99% | 25.85% | N/A |
| Revenue | N/A | N/A | 17.38% | -100% | -41.42% | 84.2% | N/A |
Health
Health Rating
BXRX has a Current Ratio of 0.30. This is a bad value and indicates that BXRX is not financially healthy enough and could expect problems in meeting its short term obligations.
Compared to an average industry Current Ratio of 3.35, BXRX is worse placed to pay its short term obligations than its industry peers. 99% of its industry peers have a better Current Ratio.
A Quick Ratio of 0.30 indicates that BXRX may have some problems paying its short term obligations.
When comparing the Quick Ratio of BXRX to the average industry Current Ratio of 2.84, BXRX is less able to pay its short term obligations than its industry peers. 98% of its industry peers have a better Quick Ratio.
BXRX has an Altman-Z score of -39.10. This is a bad value and indicates that BXRX is not financially healthy and even has some risk of bankruptcy.
When comparing the Altman-Z score of BXRX to the average industry Altman-Z score of -0.57, BXRX is less financially healthy than its industry peers. 98% of its industry peers have a better Altman-Z score.
BXRX has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for BXRX.
VS Industry
Quick Ratio (0.3) VS Industry: 2% outperformed.
-2.73
76.82
Current Ratio (0.3) VS Industry: 1% outperformed.
0.11
76.82
Altman-Z (-39.1) VS Industry: 2% outperformed.
-219.35
80.44
Dividend
Dividend Rating
No dividends for BXRX!.
BAUDAX BIO INC1.55
NASDAQ:BXRX (3/24/2023, 8:19:43 PM)-0.01 (-0.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-23 2023-02-23/bmo
Earnings (Next)05-02 2023-05-02/bmo
Inst Owners0.04%
Inst Owner Change0%
Ins Owners9.05%
Ins Owner Change0.51%
Market Cap4.01M
Analysts43.33
Price Target24.48 (1479.35%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)-22.97%
Min EPS beat(2)-23.85%
Max EPS beat(2)-22.09%
EPS beat(4)1
Avg EPS beat(4)-23.75%
Min EPS beat(4)-67.99%
Max EPS beat(4)18.94%
Revenue beat(2)N/A
Avg Revenue beat(2)-75.82%
Min Revenue beat(2)-75.82%
Max Revenue beat(2)-75.82%
Revenue beat(4)N/A
Avg Revenue beat(4)-54.5%
Min Revenue beat(4)-75.82%
Max Revenue beat(4)-25.72%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-3.37%
EPS NQ rev (3m)32.85%
EPS NY rev (1m)53.56%
EPS NY rev (3m)53.56%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3.16 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-207.53
EYN/A
EPS(NY)-4.59
Fwd EYN/A
FCF(TTM)-10.76
FCFYN/A
OCF(TTM)-10.75
OCFYN/A
SpS0.49
BVpS-9.38
TBVpS-10.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM | N/A | ||
| GM | N/A |
ROICexgc(3y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc(3y)N/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0.93% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.3 | ||
| Quick Ratio | 0.3 | ||
| Altman-Z | -39.1 |
F-Score2
WACC7.69%
ROIC/WACCN/A
Cap/Depr(3y)11.04%
Cap/Depr(5y)240.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y64.14%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-103.07%
EPS Next Y97.79%
EPS Next 2Y40.99%
EPS Next 3Y25.85%
EPS Next 5YN/A
Revenue growth 1Y17.38%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q-22.5%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y84.2%
Revenue Next 5YN/A
EBIT growth 1Y-73.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y43.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y43.59%
OCF growth 3YN/A
OCF growth 5YN/A
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Growth Stock Screener
Find more growth stocks the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA